Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4444758
Max Phase: Preclinical
Molecular Formula: C93H129N21O31S2
Molecular Weight: 2101.30
Molecule Type: Unknown
Associated Items:
ID: ALA4444758
Max Phase: Preclinical
Molecular Formula: C93H129N21O31S2
Molecular Weight: 2101.30
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(C)C[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(C)C)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)O
Standard InChI: InChI=1S/C93H129N21O31S2/c1-41(2)27-53(94)92(143)114-26-14-19-68(114)89(140)98-44(7)76(127)110-66(39-146)87(138)104-60(31-49-37-97-55-18-13-11-16-52(49)55)82(133)105-62(33-71(121)122)84(135)106-63(34-72(123)124)85(136)112-74(43(5)6)90(141)107-61(32-69(95)118)83(134)102-58(29-47-20-22-50(117)23-21-47)80(131)100-56(24-25-70(119)120)78(129)109-65(38-115)86(137)113-75(46(9)116)91(142)99-45(8)77(128)111-67(40-147)88(139)103-59(30-48-36-96-54-17-12-10-15-51(48)54)81(132)101-57(28-42(3)4)79(130)108-64(93(144)145)35-73(125)126/h10-13,15-18,20-23,36-37,41-46,53,56-68,74-75,96-97,115-117,146-147H,14,19,24-35,38-40,94H2,1-9H3,(H2,95,118)(H,98,140)(H,99,142)(H,100,131)(H,101,132)(H,102,134)(H,103,139)(H,104,138)(H,105,133)(H,106,135)(H,107,141)(H,108,130)(H,109,129)(H,110,127)(H,111,128)(H,112,136)(H,113,137)(H,119,120)(H,121,122)(H,123,124)(H,125,126)(H,144,145)/t44-,45-,46+,53-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,74-,75-/m0/s1
Standard InChI Key: RLERMXMGJZSXGH-OKGSMORNSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 2101.30 | Molecular Weight (Monoisotopic): 2099.8605 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. (2017) Inhibitory polypeptides specific to WNT inhibitors, |
Source(1):